Spruce Biosciences (SPRB)
(Delayed Data from NSDQ)
$0.43 USD
-0.01 (-3.18%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $0.42 -0.01 (-1.41%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Cash flow Statements
Fiscal Year End for Spruce Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -47.92 | -46.18 | -42.29 | -29.54 | -13.09 |
Depreciation/Amortization & Depletion | -0.57 | 0.09 | 0.19 | 0.04 | 0.01 |
Net Change from Assets/Liabilities | 10.36 | 1.13 | 1.96 | 1.16 | 0.26 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 4.85 | 3.28 | 4.27 | 0.82 | 0.20 |
Net Cash From Operating Activities | -33.28 | -41.68 | -35.88 | -27.52 | -12.62 |
Property & Equipment | -0.01 | -0.01 | -0.09 | -0.07 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 55.78 | 23.70 | -79.08 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 55.78 | 23.69 | -79.17 | -0.07 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 53.79 | 0.08 | 0.46 | 183.94 | 7.94 |
Issuance (Repayment) of Debt | -1.62 | 0.00 | 0.22 | 0.00 | 4.49 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -3.03 | -0.32 | -0.04 | -2.90 | 0.00 |
Net Cash from Financing Activities | 49.14 | -0.24 | 0.64 | 181.04 | 12.43 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 71.64 | -18.23 | -114.40 | 153.44 | -0.19 |
Cash at Beginning of Period | 24.73 | 42.96 | 157.37 | 3.92 | 4.11 |
Cash at End of Period | 96.37 | 24.73 | 42.96 | 157.37 | 3.92 |
Diluted Net EPS | -1.24 | -1.96 | -1.81 | -4.93 | NA |
Fiscal Year End for Spruce Biosciences, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -20.81 | -11.63 | -47.92 | -37.97 | -25.62 |
Depreciation/Amortization & Depletion | 0.03 | 0.02 | -0.57 | -0.52 | -0.40 |
Net Change from Assets/Liabilities | -8.66 | -4.97 | 10.36 | 12.85 | 13.82 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 3.37 | 1.62 | 4.85 | 3.57 | 2.40 |
Net Cash From Operating Activities | -26.06 | -14.96 | -33.28 | -22.07 | -9.80 |
Property & Equipment | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 55.78 | 46.48 | 32.48 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.00 | 0.00 | 55.78 | 46.48 | 32.48 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.23 | 0.18 | 53.79 | 53.72 | 53.72 |
Issuance (Repayment) of Debt | -0.81 | -0.41 | -1.62 | -1.22 | -0.81 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.01 | 0.00 | -3.03 | -2.82 | -2.82 |
Net Cash from Financing Activities | -0.59 | -0.23 | 49.14 | 49.69 | 50.10 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -26.66 | -15.19 | 71.64 | 74.10 | 72.78 |
Cash at Beginning of Period | 96.37 | 96.37 | 24.73 | 24.73 | 24.73 |
Cash at End of Period | 69.72 | 81.19 | 96.37 | 98.84 | 97.52 |
Diluted Net EPS | -0.22 | -0.28 | -0.22 | -0.30 | -0.32 |